News | November 21, 2014

AHA Study: Coordinated, Faster Emergency Response Associated with Improved Heart Attack Survival

Collaboration between paramedics and hospitals in treating heart attack patients resulted in shorter emergency department wait times, better survival

November 21, 2014 — A coordinated emergency response by healthcare teams to treat heart attack patients meant faster care that was associated with improved survival, according to research presented at the American Heart Association’s Scientific Sessions 2014.

The Regional Systems of Care Demonstration Project: Mission: Lifeline STEMI ACCELERATOR — one of the largest systems-of-care efforts to improve heart attack care — included 16 metropolitan areas comprising about 10 percent of the United States population. Researchers tracked more than 24,000 heart attack patients across 484 hospitals and 1,258 emergency medical services (EMS) agencies during the implementation phase of the project July 1, 2012-March 31, 2014.

Healthcare leadership teams across the regions established standard treatment protocols, a universal data collection system and ongoing measurement and feedback to rapidly diagnose and treat heart attack patients.

In the first 12 months of the project:

  • Patients arriving by EMS treated within 90 minutes of first medical contact increased from 54 percent to 59 percent (p = 0.0046).
  • Some regions improved more than 15 percent.


“The key to success was the collaboration between paramedics, hospital teams and interventional cardiologists working to provide care quickly,” said Christopher Granger, M.D., senior author of the study and director of the cardiac intensive care unit at Duke University Medical Center in Durham, N.C. “With in-the-field diagnosis and activation of hospital catheterization laboratories prior to hospital arrival, time spent waiting in the emergency department for the catheterization team to be available was minimized.”

Shorter emergency department (ED) times (adjusted for several covariates) were associated with improved survival (p< 0.001):

  • The death rate was 3.6 percent for patients in the ED 30 minutes or less.
  • The death rate increased to 7.0 percent for patients waiting in the ED 30-45 minutes.
  • Those waiting in the ED longer than 45 minutes had a 10.8 percent death rate. 


The project focused on ST segment elevation myocardial infarction (STEMI), the type of heart attack that occurs when a vessel supplying blood to the heart is suddenly and completely blocked. Quickly opening the blocked artery can restore normal blood flow and minimize heart damage.

Nearly half of the more than 250,000 people who have a STEMI each year in the United States aren’t treated within the recommended 90 minutes. The American Heart Association created Mission: Lifeline in 2007 to bring together hospitals, emergency medical services and communities to overcome delays in treatment. Mission: Lifeline STEMI now includes 827 community-based systems, covering 82.5 percent of the U.S. population.

The American Heart Association and regional and national leaders led the ACCELERATOR initiative, coordinated through Duke University, with the Duke Clinical Research Institute as the coordinating center.

 “These findings validate the concept that the collaborative systems-of-care model we launched with our Mission: Lifeline initiative seven years ago can speed heart attack treatment and save lives,” said Alice Jacobs, M.D., AHA past president, original chair of the AHA Mission: Lifeline Advisory Working Group and professor of medicine and Vice Chair for Clinical Affairs, Department of Medicine at Boston University Medical Center. “Lessons from the demonstration project can be used to guide our future efforts to further improve heart attack care in the U.S. and beyond.”

Co-authors are James G. Jollis, M.D.; Matthew W. Sherwood, M.D., M.H.S.; Hussein R. Al-Khalidi, Ph.D.; Mayme L. Roettig, R.N. M.S.N.; Claire C Corbett, M.M.S., N.R.EMT-P.; Harold L Dauerman, M.D.; Kathleen Fox, R.N., B.S.; J. Lee Garvey, M.D.; Timothy D Henry, M.D.; Ivan C Rokos, M.D.; B. Hadley Wilson, M.D.; Author disclosures are on the manuscript.

The Medicines Company, AstraZeneca, Philips Healthcare and Abiomed funded the study.

For more information:

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme